Immutep (IMMP) vs Rockwell Medical (RMTI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Immutep (IMMP) has outperformed Rockwell Medical (RMTI) over the past year, gaining 90.1% versus a loss of 33.7%. Over five years, IMMP leads with a -2.8% price change compared with -87.8% for RMTI. Rockwell Medical is the larger company by market cap ($32.3 million vs $28.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMMP | RMTI |
|---|---|---|
| Share price | $3.84 | $8.02 |
| Market cap | $28.30M | $32.32M |
| 1-day change | -6.56% | -2.43% |
| YTD return | +34.27% | -3.37% |
| 1-year return | +90.10% | -33.72% |
| 5-year return | -2.78% | -87.85% |
| Forward P/E | — | 114.57 |
| EPS (TTM) | $-7.30 | $-1.34 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $70.60 | $12.90 |
| 52-week low | $3.80 | $4.89 |
| Distance from 52-week high | -94.56% | -37.83% |
| Analyst consensus | none | none |
| Avg. price target upside | +681.25% | +149.38% |
| Average volume | 14.70K | 26.80K |
| Shares outstanding | 7.37M | 4.03M |
| Employees | — | 157 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Drug Manufacturers - Specialty & Generic |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IMMP has outperformed RMTI by 123.8 percentage points over the past year.
About Immutep
IMMP stock →Immutep Limited, a clinical-stage biotechnology company, develops lymphocyte activation gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases in Australia. The company's lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on the LAG-3 immune control mechanism for the treatment of cancer.
Healthcare · Biotechnology
About Rockwell Medical
RMTI stock →Rockwell Medical, Inc., together with its subsidiaries, engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. It offers citrapure citric acid concentrate, dri-sate dry acid concentrate, renalpure liquid acid concentrate, dri-sate acid concentrate mixer, renalpure acid concentrate, renalpure bicarbonate concentrate, sterilyte bicarbonate concentrate, bicarbonate cartridges, and dry acid concentrate mixer, as well as ancillary products, including 5% acetic acid, cleaner, citric acid descaler, water softener salt pellets, and other supplies used by hemodialysis providers.
Healthcare · Drug Manufacturers - Specialty & Generic · 157 employees
IMMP vs RMTI FAQ
Which is bigger, Immutep or Rockwell Medical?
Rockwell Medical (RMTI) is larger, with a market capitalization of $32.32M compared with $28.30M for Immutep (IMMP).
Which stock has performed better over the past year, IMMP or RMTI?
IMMP returned +90.10% over the past 12 months, compared with -33.72% for RMTI (price return, excluding dividends). Past performance does not predict future results.
Are Immutep and Rockwell Medical in the same industry?
Both are in the Healthcare sector, but in different industries: Biotechnology for Immutep and Drug Manufacturers - Specialty & Generic for Rockwell Medical.